Strategies for improving the management of immune-related adverse events by James L Gulley, Patrick Hwu, Gennaro Ciliberto, Aung Naing, Funda Meric-Bernstam, Michael B Atkins, Joud Hajjar

Get full text

RNA sequencing and immunohistochemistry jointly improve tumor biomarker interpretation by Vladimir Kushnarev, Danil Stupichev, Suren Davitavyan, Kirill Kriukov, Basavaraja U. Shanthappa, Anna Butusova, Sofia Menshikova, Anna Belozerova, Anastasia Shvyrkova, Arina Tkachuk, Olga Khatenkova, Linda Balabanian, Ekaterina Postovalova, Jochen K. Lennerz, Funda Meric-Bernstam, Alexander Bagaev

Get full text

Predicting pathologic ≥N2 disease in women with breast cancer by Kerollos Nashat Wanis, Wenli Dong, Yu Shen, Funda Meric-Bernstam, Taiwo Adesoye, Henry M. Kuerer, Abigail S. Caudle, Nina Tamirisa, Sarah M. DeSnyder, Susie X. Sun, Isabelle Bedrosian, Puneet Singh, Solange E. Cox, Kelly K. Hunt, Rosa F. Hwang

Get full text

Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial by Funda Meric-Bernstam, Sun Young Rha, Erika Hamilton, Yoon-Koo Kang, Diana L. Hanna, Syma Iqbal, Keun-Wook Lee, Jeeyun Lee, Muralidhar Beeram, Do-Youn Oh, Jorge Chaves, Rachel A. Goodwin, Jaffer A. Ajani, Lin Yang, Rajen Oza, Elena Elimova

Get full text

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers by Aurélien Marabelle, Aung Naing, Funda Meric-Bernstam, Xingfeng Bao, Andrea Varga, David S Hong, Aparna Parikh, Geoffrey I Shapiro, Özlem Ataman, Larisa Reyderman, Terri A Binder, Min Ren, Mingjie Liu, Satish Dayal, Amy Y Siu, Pallavi Sachdev, Lucy Xu, Vijay Bhagawati-Prasad, Ilian Tchakov, Chean Eng Ooi

Get full text

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma by Omar Alhalabi, Mohamed A. Gouda, Denái R. Milton, Hassan Ahmed Momin, Bulent Yilmaz, Bettzy Stephen, Chinenye Lynette Ejezie, Justin Tyler Moyers, Serdar A. Gurses, Jeffrey How, Siqing Fu, Jordi Rodon, David S. Hong, Sarina A. Piha‐Paul, Vivek Subbiah, Ecaterina Elena Dumbrava, Daniel D. Karp, Filip Janku, Funda Meric‐Bernstam, Nizar M. Tannir, Aung Naing

Get full text

IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer by Nicole M. Kettner, Tuyen N. Bui, Juliana Navarro-Yepes, Sanaz Ghotbaldini, Bethanie Quintela, Catherine K. Luo, Nghi Lam, Xiayu Rao, Akshara Singareeka Raghavendra, Yan Wang, Nancy Azizian, T. Kris Eckols, Moses Makokha Kasembeli, Kurt Evans, Min Yi, Hannah Wingate, Jing Wang, Aysegul A. Sahin, Funda Meric-Bernstam, Kelly K. Hunt, Senthil Damodaran, David J. Tweardy, Debu Tripathy, Khandan Keyomarsi

Get full text

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers by Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, Mark R. Lackner

Get full text